Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enfalyte (Enfamil Enfalyte) is a commercially available oral rehydration solution (ORS) designed to replace fluids and electrolytes lost during episodes of diarrhea and vomiting, typically associated with gastroenteritis. Developed by Mead Johnson (Enfamil), it is formulated with a specific balance of carbohydrates and electrolytes (sodium, potassium, and chloride) to optimize absorption and maintain low osmolality. It is available as a ready-to-use liquid in various flavors and has been evaluated in clinical trials for palatability in pediatric populations compared to other ORS products like Pedialyte.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Enfalyte.